Clofarabine
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Clofarabine |
| DrugBank ID | DB00631 |
| Brand Names (EU) | Evoltra |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.89% |
Approved Indication (EMA)
Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ? 21 years old at initial diagnosis.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acute lymphoblastic leukemia (disease) | 99.89% | DL |
| 2 | myeloid leukemia | 99.88% | DL |
| 3 | leukemia, lymphocytic, susceptibility to | 99.59% | DL |
| 4 | precursor lymphoblastic lymphoma/leukemia | 99.57% | DL |
| 5 | acute lymphoblastic/lymphocytic leukemia | 99.55% | DL |
| 6 | ganglioneuroblastoma (disease) | 99.53% | DL |
| 7 | neuroblastoma | 99.52% | DL |
| 8 | vertebral anomalies and variable endocrine and T-cell dysfunction | 99.46% | DL |
| 9 | retroperitoneal neoplasm | 99.44% | DL |
| 10 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | 99.43% | DL |
| 11 | acute lymphoblastic leukemia | 99.31% | DL |
| 12 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 99.26% | DL |
| 13 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 99.26% | DL |
| 14 | Hodgkins lymphoma | 99.13% | DL |
| 15 | precursor T-cell acute lymphoblastic leukemia | 98.86% | DL |
| 16 | bladder transitional cell carcinoma | 98.54% | DL |
| 17 | lymphoid neoplasm | 98.30% | DL |
| 18 | follicular lymphoma | 98.17% | DL |
| 19 | rheumatoid arthritis | 97.90% | DL |
| 20 | obsolete Hodgkin’s granuloma | 97.80% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.